Evidence map›Paper›PMID 42542598›Full record

ArticleMolecular therapy. Nucleic acids2026

Accurately modeling RNase H-mediated antisense oligonucleotide efficacy.

Barney Hill, Maisie R Jaques, Remya R Nair, Nicola Whiffin, Matthew J A Wood, Stephan J Sanders, Peter L Oliver, Alyssa C Hill, Carlo Rinaldi, UPNAT Consortium

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Barney HillDepartment of Paediatrics, University of Oxford, Oxford OX3 7TY, UK.
Maisie R JaquesMRC Nucleic Acid Therapy Accelerator, Harwell Research and Innovation Campus, Didcot OX11 0FA, UK.
Remya R NairMRC Nucleic Acid Therapy Accelerator, Harwell Research and Innovation Campus, Didcot OX11 0FA, UK.
Nicola WhiffinBig Data Institute and Centre for Human Genetics, University of Oxford, Oxford OX3 7LF, UK.
Matthew J A WoodDepartment of Paediatrics, University of Oxford, Oxford OX3 7TY, UK.
Stephan J SandersDepartment of Paediatrics, University of Oxford, Oxford OX3 7TY, UK.
Peter L OliverMRC Nucleic Acid Therapy Accelerator, Harwell Research and Innovation Campus, Didcot OX11 0FA, UK.
Alyssa C HillDepartment of Paediatrics, University of Oxford, Oxford OX3 7TY, UK.
Carlo RinaldiDepartment of Paediatrics, University of Oxford, Oxford OX3 7TY, UK.
UPNAT Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antisense oligonucleotides (ASOs) are a powerful class of drugs with the potential to treat a wide range of human diseases. However, the prediction of ASO efficacy remains challenging, as large-scale and costly experimental screens are typically required to identify optimal candidates for a specific therapeutic target. To address this challenge, we compiled ASO Atlas, a database comprising 188,521 RNase H-mediated ASO sequences targeting 334 unique genes with corresponding knockdown efficacy measurements extracted from published patents. Using ASO Atlas, we trained OligoAI, a deep learning model capable of jointly modeling RNA target context, ASO sequence, sugar and backbone chemistries, and dosage to predict

Indexed as

antisense oligonucleotidesartificial intelligencedeep learning modelslarge-scale datasetMT: bioinformatics

Identifiers

PMID42542598
PMCPMC13427547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.